Skip to Main Content

Paper Details

Effective drug combinations in breast, colon and pancreatic cancer cells.
Nature
121
2022
CHEK1, KRAS, TP53, basal-like breast cancer, breast, colon and pancreatic cancer, cancer, cancer cell lines, colon cancer, irinotecan, microsatellite-stable or KRAS, microsatellite-stable or KRAS-TP53 double-mutant colon cancer cells, microsatellite-stable or KRAS-mutant colon cancer, molecular subpopulations, tumour
Author NameAffiliation
Patricia JaaksWellcome Sanger Institute
Elizabeth A CokerWellcome Sanger Institute
Cyril H BenesMassachusetts General Hospital, Harvard Medical School
Andrea BertottiCandiolo Cancer Institute, FPO-IRCCS
Andrea BertottiUniversity of Torino School of Medicine
Livio TrusolinoCandiolo Cancer Institute, FPO-IRCCS
Livio TrusolinoUniversity of Torino School of Medicine
Lodewyk F A WesselsThe Netherlands Cancer Institute
Lodewyk F A WesselsOncode Institute
Lodewyk F A WesselsDelft University of Technology
Mathew J GarnettWellcome Sanger Institute
  • 1 - 11

Datasets

Release 1.2